References
1. Mills EJ, Wu P, Spurden D, Ebbert JO, and Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: A systematic review and meta-analysis. Harm Reduct J, 2009; 6:25. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19761618
2. Fant RV, Buchhalter AR, Buchman AC, and Henningfield JE. Pharmacotherapy for tobacco dependence. Handb Exp Pharmacol, 2009; (192):487-510. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19184660
3. U.S. Department of Health and Human Services. Smoking cessation. A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, 2020. Available from: https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf.
4. Wu P, Wilson K, Dimoulas P, and Mills EJ. Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health, 2006; 6:300. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17156479
5. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, et al. Pharmacotherapies for smoking cessation: A meta-analysis of randomized controlled trials. CMAJ, 2008; 179(2):135-44. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18625984
6. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, and Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews, 2018; 5:CD000146. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29852054
7. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, and Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews, 2014; 1(1):CD000031. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24402784
8. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, and Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, 2016; 5(5):CD006103. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27158893
9. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, 2019; 4(4):CD013308. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30997928
10. Cahill K, Stevens S, Perera R, and Lancaster T. Pharmacological interventions for smoking cessation: An overview and network meta-analysis. Cochrane Database of Systematic Reviews, 2013; 5(5):CD009329. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23728690
11. Fix BV, Hyland A, Rivard C, McNeill A, Fong GT, et al. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: Findings from the 2006-2008 international tobacco control (ITC) four country survey. International Journal of Environmental Research and Public Health, 2011; 8(1):222-33. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21318025
12. Narayanan S, Ebbert JO, and Sood A. Gender differences in self-reported use, perceived efficacy, and interest in future use of nicotine-dependence treatments: A cross-sectional survey in adults at a tertiary care center for nicotine dependence. Gend Med, 2009; 6(2):362-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19682663
13. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, 2012; 11:CD000146. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23152200
14. Pharmaceutical Benefits Advisory Committee. March 2008 meeting, positive recommendations. 2008. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-mar08-positive.
15. Pharmaceutical Benefits Advisory Committee. Letter concerning listing of NRT patches for Indigenous smokers, The Cancer Council Australia, Editor 2008: Sydney.
16. Australian Government Department of Health. Australian register of therapeutic goods, medicines 2019. Available from: https://www.ebs.tga.gov.au/.
17. Australian Government Department of Health. Pharmaceutical benefits scheme – what are the current patient fees and charges? 2020. Available from: http://www.pbs.gov.au/info/about-the-pbs#What_are_the_current_patient_fees_and_charges.
18. US Department of Health and Human Services. The health consequences of smoking: Nicotine addiction. A report of the Surgeon General. Rockville, Maryland: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, 1988. Available from: http://profiles.nlm.nih.gov/NN/B/B/Z/D/_/nnbbzd.pdf.
19. Hughes JR. The future of smoking cessation therapy in the United States. Addiction, 1996; 91(12):1797-802. Available from: https://www.ncbi.nlm.nih.gov/pubmed/8997761
20. Paul C, Walsh R, and Girgis A. Nicotine replacement therapies over the counter: Real life use in the Australian community. Australian & New Zealand Journal of Public Health, 2003; 27(5):491–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14651392
21. Henningfield JE, Fant RV, Buchhalter AR, and Stitzer ML. Pharmacotherapy for nicotine dependence. CA: A Cancer Journal for Clinicians, 2005; 55(5):281-99; quiz 322-3, 5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16166074
22. Kraiczi H, Hansson A, and Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. Nicotine & Tobacco Research, 2011; 13(12):1176-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21849415
23. Lindblom EN. Effectively regulating e-cigarettes and their advertising—and the first amendment. Food & Drug Law Journal, 2015; 70:57–94. Available from: http://www.law.georgetown.edu/oneillinstitute/news/documents/March10-LindblomFDLJ_001.pdf
24. Polosa R and Benowitz NL. Treatment of nicotine addiction: Present therapeutic options and pipeline developments. Trends Pharmacol Sci, 2011; 32(5):281-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21256603
25. World Health Organization. Tools for advancing tobacco control in the xx1st century: Policy recommendations for smoking cessation and treatment of tobacco dependence. Tools for public health. Geneva: World Health Organization, 2003. Available from: http://www.wpro.who.int/NR/rdonlyres/8D25E4D3-BB81-479E-8DF5-7BAF674DB104/0/PolicyRecommendations.pdf.
26. Beaver JD, Long CJ, Cole DM, Durcan MJ, Bannon LC, et al. The effects of nicotine replacement on cognitive brain activity during smoking withdrawal studied with simultaneous fmri/eeg. Neuropsychopharmacology, 2011; 36(9):1792-800. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21544072
27. Shiffman S. Nicotine replacement therapy for smoking cessation in the "real world". Thorax, 2007; 62(11):930–1. Available from: http://thorax.bmj.com/cgi/content/full/62/11/930
28. Stanley TD and Massey S. Evidence of nicotine replacement's effectiveness dissolves when meta-regression accommodates multiple sources of bias. J Clin Epidemiol, 2016; 79:41-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27079846
29. Hughes JR, Fanshawe TR, and Stead LF. Is nicotine replacement really ineffective? A reply to stanley and massey. J Clin Epidemiol, 2017; 81:143-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27663610
30. Stanley TD. Yes, nicotine replacement therapy's effectiveness is much lower than often reported. J Clin Epidemiol, 2017; 81:144-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27650384
31. Green G. Nicotine replacement therapy for smoking cessation. American Family Physician, 2015; 92(1):24A-B. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26132134
32. Etter JF and Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: A meta-analysis. Tobacco Control, 2006; 15(4):280-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16885576
33. Shiffman S. Effect of nicotine lozenges on affective smoking withdrawal symptoms: Secondary analysis of a randomized, double-blind, placebo-controlled clinical trial. Clinical Therapeutics, 2008; 30(8):1461-75. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18803988
34. Pack QR, Jorenby DE, Fiore MC, Jackson T, Weston P, et al. A comparison of the nicotine lozenge and nicotine gum: An effectiveness randomized controlled trial. WMJ, 2008; 107(5):237-43. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18777992
35. Shiffman S, Ferguson SG, Rohay J, and Gitchell JG. Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: Relationship with use and compliance. Addiction, 2008; 103(8):1371–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18855827
36. Perkins KA, Briski J, Fonte C, Scott J, and Lerman C. Severity of tobacco abstinence symptoms varies by time of day. Nicotine & Tobacco Research, 2009; 11(1):84-91. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19246445
37. Brokowski L, Chen J, and Tanner S. High-dose transdermal nicotine replacement for tobacco cessation. American Journal of Health System Pharmacy, 2014; 71(8):634-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24688036
38. Fiore MC, Jaén M, Carlos Roberto, Baker TB, Bailey WC, Benowitz NL, et al. Treating tobacco use and dependence. Clinical practice guidelines. Rockville, MD: US Department of Health and Human Services, 2008. Available from: http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/update/index.html.
39. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, et al. Efficacy of a nicotine lozenge for smoking cessation. Archives of Internal Medicine, 2002; 162(11):1267-76. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12038945
40. Strong DR, David SP, Johnstone EC, Aveyard P, Murphy MF, et al. Differential efficacy of nicotine replacement among overweight and obese women smokers. Nicotine & Tobacco Research, 2015; 17(7):855-61. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25481918
41. Scherphof CS, van den Eijnden RJ, Engels RC, and Vollebergh WA. Long-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: A randomized controlled trial. Drug and Alcohol Dependence, 2014; 140:217-20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24811201
42. Fucito LM, Bars MP, Forray A, Rojewski AM, Shiffman S, et al. Addressing the evidence for FDA nicotine replacement therapy label changes: A policy statement of the association for the treatment of tobacco use and dependence and the society for research on nicotine and tobacco. Nicotine & Tobacco Research, 2014; 16(7):909-14. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24919399
43. Schneider NG, Cortner C, Gould JL, Koury MA, and Olmstead RE. Comparison of craving and withdrawal among four combination nicotine treatments. Hum Psychopharmacol, 2008; 23(6):513-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18438964
44. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry, 2009; 66(11):1253-62. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19884613
45. Gonzales D. Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. Evid Based Med, 2010; 15(3):77-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20522682
46. Prochazka AV. Acp journal club. Nicotine patch plus nicotine lozenges increased smoking cessation rate more than placebo. Annals of Internal Medicine, 2010; 152(10):JC5-2. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20479019
47. Windle SB, Filion KB, Mancini JG, Adye-White L, Joseph L, et al. Combination therapies for smoking cessation: A hierarchical bayesian meta-analysis. American Journal of Preventive Medicine, 2016; 51(6):1060-71. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27617367
48. Carpenter MJ, Jardin BF, Burris JL, Mathew AR, Schnoll RA, et al. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: A review of the literature. Drugs, 2013; 73(5):407-26. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23572407
49. Le Foll B and George T. Treatment of tobacco dependence: Integrating recent progress into practice. Canadian Medical Association Journal, 2007; 177(11):1373–80. Available from: http://www.cmaj.ca/cgi/content/full/177/11/1373
50. Ferguson SG and Shiffman S. Effect of high-dose nicotine patch on the characteristics of lapse episodes. Health Psychology, 2010; 29(4):358-66. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20658822
51. Cunningham JA, Kushnir V, Selby P, Tyndale RF, Zawertailo L, et al. Effect of mailing nicotine patches on tobacco cessation among adult smokers : A randomized clinical trial. JAMA Internal Medicine, 2016; 176(2):184–90. Available from: http://dx.doi.org/10.1001/jamainternmed.2015.7792
52. Hughes JR, Shiffman S, Callas P, and Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tobacco Control, 2003; 12(1):21-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12612357
53. West R and Zhou X. Is nicotine replacement therapy for smoking cessation effective in the 'real world'? Findings from a prospective multinational cohort study. Thorax, 2007; 62(998-1002). Available from: http://www.ncbi.nlm.nih.gov/pubmed/17573444
54. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, et al. Effectiveness of extended-duration transdermal nicotine therapy: A randomized trial. Annals of Internal Medicine, 2010; 152(3):144-51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20124230
55. Zwar N, Richmond R, Borland R, Stillman S, Cunninghan M, et al., Smoking cessation guidelines for Australian general practice: Practice handbook. Vol. 4 July 2004.Canberra: Department of Health and Ageing; 2004. Available from: http://www.health.gov.au/pubhlth/publicat/document/smoking_cessation.pdf.
56. Shiffman S, Khayrallah M, and Nowak R. Efficacy of the nicotine patch for relief of craving and withdrawal 7-10 weeks after cessation. Nicotine & Tobacco Research, 2000; 2(4):371-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11197318
57. Hajek P, McRobbie H, and Gillison F. Dependence potential of nicotine replacement treatments: Effects of product type, patient characteristics, and cost to user. Preventive Medicine, 2007; 44(3):230-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17207524
58. Berrettini WH and Lerman CE. Pharmacotherapy and pharmacogenetics of nicotine dependence. American Journal of Psychiatry, 2005; 162(8):1441-51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16055765
59. Zhang B, Cohen JE, Bondy SJ, and Selby P. Duration of nicotine replacement therapy use and smoking cessation: A population-based longitudinal study. American Journal of Epidemiology, 2015; 181(7):513-20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25740789
60. Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, et al. Relapse prevention interventions for smoking cessation. Cochrane Database of Systematic Reviews, 2019; 2(2):CD003999. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30758045
61. Zapawa LM, Hughes JR, Benowitz NL, Rigotti NA, and Shiffman S. Cautions and warnings on the US otc label for nicotine replacement: What's a doctor to do? Addictive Behaviors, 2011; 36(4):327-32. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21220188
62. Beard E, Bruguera C, McNeill A, Brown J, and West R. Association of amount and duration of NRT use in smokers with cigarette consumption and motivation to stop smoking: A national survey of smokers in England. Addictive Behaviors, 2015; 40:33-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25218069
63. Borland R, Cooper J, McNeill A, O'Connor R, and Cummings KM. Trends in beliefs about the harmfulness and use of stop-smoking medications and smokeless tobacco products among cigarettes smokers: Findings from the ITC four-country survey. Harm Reduct J, 2011; 8:21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21859499
64. Balmford J, Borland R, Hammond D, and Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: Data from the ITC four-country survey. Nicotine & Tobacco Research, 2011; 13(2):94-102. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21147894
65. Burns E and Levinson A. Discontinuation of nicotine replacement therapy among smoking-cessation attempters. American Journal of Preventive Medicine, 2008; 34(3):212–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18312809
66. Raupach T and van Schayck CP. Pharmacotherapy for smoking cessation: Current advances and research topics. CNS Drugs, 2011; 25(5):371-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21476609
67. Vogt F, Hall S, and Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: Qualitative and quantitative studies Nicotine & Tobacco Research, 2008; 10(8):1405–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18686189
68. Weiss SM and Smith-Simone SY. Consumer and health literacy: The need to better design tobacco-cessation product packaging, labels, and inserts. American Journal of Preventive Medicine, 2010; 38(3 Suppl):S403-13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20176315
69. Schneider N, Cortner C, Justice M, Gould J, Amor C, et al. Preferences among five nicotine treatments based on information versus sampling. Nicotine & Tobacco Research, 2008; 10(1):179–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18188758
70. Canadian Agency for Drugs and Technologies in Health. Nicotine replacement therapy for smoking cessation or reduction: A review of the clinical evidence. CADTH Rapid Response Reports, 2014. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24741730
71. Hammond D, Reid JL, Driezen P, Cummings KM, Borland R, et al. Smokers' use of nicotine replacement therapy for reasons other than stopping smoking: Findings from the ITC four country survey. Addiction, 2008; 103(10):1696–703. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18821877
72. Zwar N, Bell J, Peters M, Christie M, and Mendelsohn C. Nicotine and nicotine replacement therapy – the facts. Australian Pharmacist, 2006; 25(12):969–73. Available from: www.psa.org.au/site.php?id=1458
73. Fant RV, Owen LL, and Henningfield JE. Nicotine replacement therapy. Prim Care, 1999; 26(3):633-52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10436291
74. Stead LF and Lancaster T Interventions to reduce harm from continued tobacco use. Cochrane Database of Systematic Reviews, 2007 DOI: 10.1002/14651858.CD005231.pub2. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005231/frame.html
75. Stepanov I, Carmella S, Han S, Pinto A, Strasser A, et al. Evidence for endogenous formation of n'-nitrosonornicotine in some long-term nicotine patch users. Nicotine & Tobacco Research, 2009; 11(1):99–105. Available from: http://ntr.oxfordjournals.org/cgi/content/full/ntn020v1
76. Etter JF. Addiction to the nicotine gum in never smokers. BMC Public Health, 2007; 7(147):159. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17640334
77. Perkins KA. Nicotine self-administration. Nicotine & Tobacco Research, 1999; 1 Suppl 2(suppl. 2):S133-7; discussion S9-40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11768171
78. Pharmacia Australia. Product information. Nicorette chewing gum. 2mg & 4mg. [leaflet], July 2003, Pharmacia Australia Pty Limited: Rydalmere, NSW.
79. Pharmacia Australia. Product information. Nicorette inhaler. [leaflet] July 2003, Pharmacia Australia Pty Limited: Rydalmere, NSW.
80. Pharmacia Australia. Product information. Nicorette microtab. 2mg sublingual tablets. [leaflet], October 2003, Pharmacia Australia Pty Limited: Rydalmere, NSW.
81. GlaxoSmithKline. Nicobate cq lozenges 2/4mg. [leaflet]. January Ermington NSE: GlaxoSmithKline, 2002.
82. Mills EJ, Wu P, Lockhart I, Wilson K, and Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tobacco Induced Diseases, 2010; 8(1):8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20626883
83. Agboola S, McNeill A, Coleman T, and Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction, 2010; 105(8):1362-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20653619
84. Zwar N, Richmond R, Borland R, Peters M, Stillman S, et al. Smoking cessation pharmacotherapy: An update for health professionals. Melbourne: Royal Australian College of General Practitioners, 2007. Available from: http://www.treatobacco.net/en/uploads/documents/Treatment%20Guidelines/Australia%20treatment%20guidelines%20-%20pharmacotherapy%20in%20English%202007.pdf.
85. Bansal MA, Cummings KM, Hyland A, and Giovino GA. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them? Nicotine & Tobacco Research, 2004; 6 Suppl 3(suppl. 3):S303-10. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15799593
86. U.S. Department of Health and Human Services. The health consequences of smoking: 50 years of progress. A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. Available from: http://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf.
87. Zheng Y, Ritzenthaler J, Roman J, and Han S. Nicotine stimulates human lung cancer cell growth by inducing fironectin expression. American Journal of Respiratory Cell and Molecular Biology, 2007; 28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17600315
88. Wong H, Yu L, Lam E, Tai E, Wue W, et al. Nicotine promotes colon tumour growth and angiogenesis through beta-adrenergic activation. Toxicological Sciences, 2007; 97(2):279–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17369603
89. Shiffman S and Ferguson SG. Nicotine patch therapy prior to quitting smoking: A meta-analysis. Addiction, 2008; 103(4):557-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18339101
90. Shiffman S, Ferguson S, and Strahs K. Quitting by gradual smoking reduction using nicotine gum: A randomized controlled trial. American Journal of Preventive Medicine, 2009; 36(2):96–104.e1. Available from: http://www.ajpm-online.net/article/S0749-3797(08)00891-X/fulltext
91. Dalack GW and Meador-Woodruff JH. Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine & Tobacco Research, 1999; 1(1):53-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11072388
92. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, et al. Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety. British Medical Journal, 2000; 321(7257):329-33. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10926587
93. Fagerstrom KO, Tejding R, Westin A, and Lunell E. Aiding reduction of smoking with nicotine replacement medications: Hope for the recalcitrant smoker? Tobacco Control, 1997; 6(4):311-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9583629
94. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: Systematic review and meta-analysis. British Medical Journal, 2009; 338:b1024. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19342408
95. Etter JF and Laszlo E. Postintervention effect of nicotine replacement therapy for smoking reduction: A randomized trial with a 5-year follow-up. J Clin Psychopharmacol, 2007; 27(2):151-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17414237
96. Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, et al. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: A systematic review of effectiveness and economic analysis. Health Technology Assessment, 2008; 12(2):1–135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18093448
97. Quit Victoria. Nicotine replacement products. 2016. Available from: http://www.quit.org.au/preparing-to-quit/choosing-best-way-to-quit/nicotine-replacement-products
98. Winstanley M, Woodward S, and Walker N, Tobacco in Australia; facts and issues 1995; 2nd edition. Vol. 2.Carlton South: Victorian Smoking and Health Program; 1995. Available from: http://www.quit.org.au/quit/FandI/welcome.htm.
99. Carter S, Borland R, and Chapman C. Finding the strength to kill your best friend–smokers talk about smoking and quitting. Sydney: Australian Smoking Cessation Consortium and GlaxoSmithKline Consumer Healthcare, 2001. Available from: http://tobacco.health.usyd.edu.au/site/supersite/resources/pdfs/killbestfriend.pdf.
100. Chapman S, Relapse and other realities: An update on smoking cessation rates in Australia. SmithKline Beecham; (World No Tobacco Day) 2000.
101. Richmond R and Zwar N. Review of bupropion for smoking cessation. Drug Alcohol Rev, 2003; 22(2):203-20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12850907
102. Lancaster T, Stead L, and Cahill K. An update on therapeutics for tobacco dependence. Expert Opin Pharmacother, 2008; 9(1):15-22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18076335
103. Kotlyar M, Drone D, Thuras P, Hatsukami DK, Brauer L, et al. Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. Nicotine & Tobacco Research, 2011; 13(6):492-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21378081
104. Paterson NE. Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: Recent preclinical and clinical insights. Eur J Pharmacol, 2009; 603(1-3):1-11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19101536
105. Culbertson CS, Bramen J, Cohen MS, London ED, Olmstead RE, et al. Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers. Arch Gen Psychiatry, 2011; 68(5):505-15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21199957
106. Rovina N, Nikoloutsou I, Katsani G, Dima E, Fransis K, et al. Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice. Ther Adv Respir Dis, 2009; 3(6):279-87. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19934280
107. Fucito LM, Toll BA, Salovey P, and O'Malley SS. Beliefs and attitudes about bupropion: Implications for medication adherence and smoking cessation treatment. Psychology of Addictive Behaviors, 2009; 23(2):373-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19586156
108. Hawk LW, Jr., Ashare RL, Rhodes JD, Oliver JA, Cummings KM, et al. Does extended pre quit bupropion aid in extinguishing smoking behavior? Nicotine & Tobacco Research, 2015; 17(11):1377-84. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25589680
109. Tomaz PR, Santos JR, Issa JS, Abe TO, Gaya PV, et al. Cyp2b6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. European Journal of Clinical Pharmacology, 2015; 71(9):1067-73. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26153084
110. Zwar N, Nasser A, Comino E, and Richmond R. Short-term effectiveness of bupropion for assisting smoking cessation in general practice. Medical Journal of Australia, 2003; 177(5):277–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12197829
111. Kittle J, Lopes RD, Huang M, Marquess ML, Wilson MD, et al. Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. Clin Cardiol, 2017; 40(10):899-906. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28605035
112. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (eagles): A double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016; 387(10037):2507-20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27116918
113. Holmes S, Zwar N, Jimenez-Ruiz C, Ryan P, Browning D, et al. Bupropion as an aid to smoking cessation: A review of real-life effectiveness. International Journal of Clinical Practice, 2004; 58(3):285−91. Available from: http://www3.interscience.wiley.com/journal/118807867/abstract
114. Roddy E. Bupropion and other non-nicotine pharmacotherapies. British Medical Journal, 2004; 328(7438):509-11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/14988194
115. Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, et al. Selegiline transdermal system (sts) as an aid for smoking cessation. Nicotine & Tobacco Research, 2012; 14(3):377-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21846661
116. McDonough M. Update on medicines for smoking cessation. Australian Prescriber, 2015; 38(4):106-11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26648633
117. Pfizer Australia Pty Ltd. Product information champix® (varenicline as tartrate) pfpchamt10108. Canberra 2008. Available from: http://www.pbs.gov.au/pi/pfpchamt10108.pdf.
118. Williams JM, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, et al. Varenicline for tobacco dependence: Panacea or plight? Expert Opin Pharmacother, 2011; 12(11):1799-812. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21644843
119. Brandon TH, Drobes DJ, Unrod M, Heckman BW, Oliver JA, et al. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology (Berl), 2011; 218(2):391-403. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21559801
120. Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, et al. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clinical Pharmacokinetics, 2010; 49(12):799-816. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21053991
121. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, et al. Effects of varenicline on smoking cue-triggered neural and craving responses. Arch Gen Psychiatry, 2011; 68(5):516-26. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21199958
122. Fedota JR, Sutherland MT, Salmeron BJ, Ross TJ, Hong LE, et al. Reward anticipation is differentially modulated by varenicline and nicotine in smokers. Neuropsychopharmacology, 2015; 40(8):2038-46. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25742873
123. Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, et al. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biological Psychiatry, 2010; 67(8):715-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20207347
124. Pascual FP, Fontoba Ferrandiz J, Gil Sanchez MC, Ponce Lorenzo F, and Botella Estrella C. Two-year therapeutic effectiveness of varenicline for smoking cessation in a real world setting. Substance Use and Misuse, 2016; 51(2):131-40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26829065
125. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, et al. Effect of varenicline on smoking cessation through smoking reduction: A randomized clinical trial. Journal of the American Medical Association, 2015; 313(7):687-94. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25688780
126. Carson KV, Smith BJ, Brinn MP, Peters MJ, Fitridge R, et al. Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: A randomized controlled trial for inpatients (stop study). Nicotine & Tobacco Research, 2014; 16(11):1495-502. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25031315
127. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association, 2006; 296(1):47-55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16820546
128. Howard P, Knight C, Bolar A, and Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the benesco simulation model: Application to a population of US adult smokers. PharmacoEconomics, 2008; 26(6):497–511. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18489200
129. Annemans L, Nackaerts K, Bartsch P, Prignot J, and Marbaix S. Cost effectiveness of varenicline in belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: A benesco markov cost-effectiveness analysis. Clin Drug Investig, 2009; 29(10):655-65. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19715382
130. Bae JY, Kim CH, and Lee EK. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea. Value Health, 2009; 12 Suppl 3:S70-3. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20586986
131. Bolin K, Mork AC, and Wilson K. Smoking-cessation therapy using varenicline: The cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J Eval Clin Pract, 2009; 15(3):478-85. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19536915
132. Igarashi A, Takuma H, Fukuda T, and Tsutani K. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. PharmacoEconomics, 2009; 27(3):247-61. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19354344
133. Jimenez-Ruiz C, Berlin I, and Hering T. Varenicline: A novel pharmacotherapy for smoking cessation. Drugs, 2009; 69(10):1319-38. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19583451
134. Keiding H. Cost-effectiveness of varenicline for smoking cessation. Expert Rev Pharmacoecon Outcomes Res, 2009; 9(3):215-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19527093
135. Fagerstrom K and Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat, 2008; 4(2):353-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18728741
136. Fagerstrom K, Nakamura M, Cho HJ, Tsai ST, Wang C, et al. Varenicline treatment for smoking cessation in asian populations: A pooled analysis of placebo-controlled trials conducted in six asian countries. Curr Med Res Opin, 2010; 26(9):2165-73. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20666691
137. Ebbert JO, Croghan IT, North F, and Schroeder DR. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine & Tobacco Research, 2010; 12(10):1037-40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20724382
138. Ebbert J, Montori VM, Erwin PJ, and Stead LF. Interventions for smokeless tobacco use cessation. Cochrane Database of Systematic Reviews, 2011; 2(2):CD004306. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21328266
139. Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, et al. Effects of varenicline in adult smokers: A multinational, 24-week, randomized, double-blind, placebo-controlled study. Clinical Therapeutics, 2011; 33(4):465-77. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21635992
140. Boudrez H, Gratziou C, Messig M, and Metcalfe M. Effectiveness of varenicline as an aid to smoking cessation: Results of an inter-European observational study. Curr Med Res Opin, 2011; 27(4):769-75. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21294601
141. Ebbert JO, Croghan IT, Hurt RT, Schroeder DR, and Hays JT. Varenicline for smoking cessation in light smokers. Nicotine & Tobacco Research, 2016; 18(10):2031-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27117285
142. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. Journal of the American Medical Association, 2006; 296(1):56-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16820547
143. Potts LA and Garwood CL. Varenicline: The newest agent for smoking cessation. American Journal of Health System Pharmacy, 2007; 64(13):1381-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17592002
144. Aubin H, Bobak A, Britton J, Oncken C, Billing C, et al. Authors’ reply. Thorax, 2008; 63:752–3 Available from: http://thorax.bmj.com/cgi/content/full/63/8/752
145. Nides M, Glover ED, Reus VI, Christen AG, Make BJ, et al. Varenicline versus bupropion sr or placebo for smoking cessation: A pooled analysis. American Journal of Health Behavior, 2008; 32(6):664-75. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18442345
146. Hind D, Tappenden P, Peters J, and Kenjegalieva K. Varenicline in the management of smoking cessation: A single technology appraisal. Health Technology Assessment, 2009; 13 Suppl 2( Suppl 2):9-13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19804684
147. Cahill K, Stead L, and Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf, 2009; 32(2):119-35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19236119
148. Kotz D, Brown J, and West R. Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world". BMC Public Health, 2014; 14:1163. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25392075
149. Gray KM, McClure EA, Baker NL, Hartwell KJ, Carpenter MJ, et al. An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. Addiction, 2015; 110(6):1027-34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25727442
150. Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: A randomized clinical trial. Journal of the American Medical Association, 2016; 315(4):371-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26813210
151. Lee JH, Jones PG, Bybee K, and O'Keefe JH. A longer course of varenicline therapy improves smoking cessation rates. Prev Cardiol, 2008; 11(4):210-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19476573
152. Keating GM and Lyseng-Williamson KA. Varenicline: A pharmacoeconomic review of its use as an aid to smoking cessation. PharmacoEconomics, 2010; 28(3):231-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20108995
153. Burke MV, Hays JT, and Ebbert JO. Varenicline for smoking cessation: A narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. Patient Prefer Adherence, 2016; 10:435-41. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27099479
154. Hajek P, Tonnesen P, Arteaga C, Russ C, and Tonstad S. Varenicline in prevention of relapse to smoking: Effect of quit pattern on response to extended treatment. Addiction, 2009; 104(9):1597-602. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19686530
155. Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: A randomized, placebo-controlled trial. Clinical Pharmacology and Therapeutics, 2014; 96(3):390-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24911368
156. Hajek P, McRobbie H, Myers Smith K, Phillips A, Cornwall D, et al. Increasing varenicline dose in smokers who do not respond to the standard dosage: A randomized clinical trial. JAMA Internal Medicine, 2015; 175(2):266-71. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25545858
157. Jung JW, Jeon EJ, Kim JG, Yang SY, Choi JC, et al. Clinical experience of varenicline for smoking cessation. Clin Respir J, 2010; 4(4):215-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20887344
158. Grassi MC, Enea D, Ferketich AK, Lu B, Pasquariello S, et al. Effectiveness of varenicline for smoking cessation: A 1-year follow-up study. Journal of Substance Abuse Treatment, 2011; 41(1):64-70. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21349681
159. Rocha Santos J, Tomaz PR, Issa JS, Abe TO, Krieger JE, et al. Chrna4 rs1044396 is associated with smoking cessation in varenicline therapy. Frontiers in Genetics, 2015; 6:46. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25774163
160. Pharmaceutical Benefits Scheme. Varenicline. Available from: https://www.pbs.gov.au/medicine/item/5469W-9128K-9129L
161. Garrison GD and Dugan SE. Varenicline: A first-line treatment option for smoking cessation. Clinical Therapeutics, 2009; 31(3):463-91. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19393839
162. Kasza KA, Cummings KM, Carpenter MJ, Cornelius ME, Hyland AJ, et al. Use of stop-smoking medications in the United States before and after the introduction of varenicline. Addiction, 2015; 110(2):346-55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25331778
163. von Wartburg M, Raymond V, and Paradis PE. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. Other smoking cessation strategies in Canada. International Journal of Clinical Practice, 2014; 68(5):639-46. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24472120
164. Galanti LM. Tobacco smoking cessation management: Integrating varenicline in current practice. Vasc Health Risk Manag, 2008; 4(4):837-45. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19066000
165. Leung LK, Patafio FM, and Rosser WW. Gastrointestinal adverse effects of varenicline at maintenance dose: A meta-analysis. BMC Clin Pharmacol, 2011; 11:15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21955317
166. McIntosh J. Chantix could affect patients' alcohol tolerance, warn FDA. Medical News Today, 2015. Available from: http://www.medicalnewstoday.com/articles/290654.php?tw
167. Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West R, et al. Cardiovascular and neuropsychiatric risks of varenicline: A retrospective cohort study. The Lancet Respiratory Medicine, 2015; 3(10):761-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26355008
168. Mills EJ, Thorlund K, Eapen S, Wu P, and Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: A network meta-analysis. Circulation, 2014; 129(1):28-41. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24323793
169. Sharma A, Thakar S, Lavie CJ, Garg J, Krishnamoorthy P, et al. Cardiovascular adverse events associated with smoking-cessation pharmacotherapies. Current Cardiology Reports, 2015; 17(1):554. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25410148
170. Wu Q, Gilbody S, Peckham E, Brabyn S, and Parrott S. Varenicline for smoking cessation and reduction in people with severe mental illnesses: Systematic review and meta-analysis. Addiction, 2016; 111(9):1554-67. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27043328
171. Therapeutic Goods Administration, Varenicline (champix): Safety advisory – risks of psychiatric symptoms and potential interaction with alcohol. Australian Government; 2015. Available from: https://www.tga.gov.au/alert/varenicline-champix.
172. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clinical Pharmacology and Therapeutics, 2011; 89(3):392-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21270788
173. Cerny EH and Cerny T. Vaccines against nicotine. Hum Vaccin, 2009; 5(4):200-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19276649
174. Casella G, Caponnetto P, and Polosa R. Therapeutic advances in the treatment of nicotine addiction: Present and future. Ther Adv Chronic Dis, 2010; 1(3):95-106. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23251732
175. Escobar-Chavez JJ, Dominguez-Delgado CL, and Rodriguez-Cruz IM. Targeting nicotine addiction: The possibility of a therapeutic vaccine. Drug Des Devel Ther, 2011; 5:211-24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21607018
176. Havermans A, Vuurman EF, van den Hurk J, Hoogsteder P, and van Schayck OC. Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task. Addiction, 2014; 109(8):1260-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24894701
177. Tonstad S, Heggen E, Giljam H, Lagerback PA, Tonnesen P, et al. Niccine(r), a nicotine vaccine, for relapse prevention: A phase ii, randomized, placebo-controlled, multicenter clinical trial. Nicotine & Tobacco Research, 2013; 15(9):1492-501. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23471101
178. Fahim RE, Kessler PD, and Kalnik MW. Therapeutic vaccines against tobacco addiction. Expert Review of Vaccines, 2013; 12(3):333-42. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23496672
179. Pentel PR and LeSage MG. New directions in nicotine vaccine design and use. Adv Pharmacol, 2014; 69:553-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24484987
180. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology and Therapeutics, 2005; 78(5):456-67. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16321612
181. Maurer P and Bachmann MF. Vaccination against nicotine: An emerging therapy for tobacco dependence. Expert Opin Investig Drugs, 2007; 16(11):1775-83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17970637
182. Cerny EH and Cerny T. Anti-nicotine abuse vaccines in the pipeline: An update. Expert Opin Investig Drugs, 2008; 17(5):691-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18447595
183. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, et al. A vaccine against nicotine for smoking cessation: A randomized controlled trial. PLoS ONE, 2008; 3(6):e2547. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18575629
184. Fattom AI, Hohenboken M, and Kalnik M, Nicvax®, a nicotine conjugate vaccine, aids smokers to quit smoking and stay quit: Animal and human data in support of a proposed mechanism of action. The eleventh annual conference on vaccine research Baltimore, MD 2008. Available from: http://www.nfid.org/pdf/conferences/vaccine08abstracts.pdf.
185. Lockner JW, Lively JM, Collins KC, Vendruscolo JC, Azar MR, et al. A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity. Journal of Medicinal Chemistry, 2015; 58(2):1005-11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25493909
186. Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, et al. Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: Effectiveness in clinical practice. Addiction, 2013; 108(12):2193-201. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23859696
187. Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, et al. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: A systematic review and meta-analysis of randomized controlled trials. BMC Public Health, 2015; 15(1):689. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26198192
188. Vogeler T, McClain C, and Evoy KE. Combination bupropion sr and varenicline for smoking cessation: A systematic review. American Journal of Drug and Alcohol Abuse, 2016; 42(2):129-39. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26809272
189. Kotz D, Brown J, and West R. 'Real-world' effectiveness of smoking cessation treatments: A population study. Addiction, 2014; 109(3):491-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24372901
190. Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, et al. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: A review of reviews for the u.S. Preventive services task force. Annals of Internal Medicine, 2015; 163(8):608-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26389650
191. Stead LF, Koilpillai P, Fanshawe TR, and Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database of Systematic Reviews, 2016; 3:CD008286. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27009521
192. Hartmann-Boyce J, Hong B, Livingstone-Banks J, Wheat H, and Fanshawe TR. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database of Systematic Reviews, 2019; 6:CD009670. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31166007
193. Etter JF, Lukas RJ, Benowitz NL, West R, and Dresler CM. Cytisine for smoking cessation: A research agenda. Drug and Alcohol Dependence, 2008; 92(1-3):3-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17825502
194. Hajek P, McRobbie H, and Myers K. Efficacy of cytisine in helping smokers quit: Systematic review and meta-analysis. Thorax, 2013; 68(11):1037-42. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23404838
195. Tutka P, Vinnikov D, Courtney RJ, and Benowitz NL. Cytisine for nicotine addiction treatment: A review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction, 2019; 114(11):1951-69. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31240783
196. Walker N, Howe C, Glover M, McRobbie H, Barnes J, et al. Cytisine versus nicotine for smoking cessation. New England Journal of Medicine, 2014; 371(25):2353-62. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25517706
197. Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Health Technology Assessment, 2014; 18(33):1-120. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24831822
198. Gourlay SG, Stead LF, and Benowitz NL Clonidine for smoking cessation. Cochrane Database of Systematic Reviews, 2004 DOI: 10.1002/14651858.CD000058.pub2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15266422
199. Lancaster T and Stead LF. Silver acetate for smoking cessation. Cochrane Database of Systematic Reviews, 2012; 9(9):CD000191. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22972041
200. Rose JE. Disrupting nicotine reinforcement: From cigarette to brain. Ann N Y Acad Sci, 2008; 1141:233-56. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18991961
201. Siu EC and Tyndale RF. Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol, 2007; 47:541-64. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17209799
202. Cahill K and Ussher M Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database of Systematic Reviews, 2007 DOI: 10.1002/14651858.CD005353.pub3. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005353/frame.html
203. Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, et al. Efficacy of n-acetylcysteine in the treatment of nicotine dependence: A double-blind placebo-controlled pilot study. Eur Addict Res, 2011; 17(4):211-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21606648
204. Asevedo E, Mendes AC, Berk M, and Brietzke E. Systematic review of n-acetylcysteine in the treatment of addictions. Braz J Psychiatry, 2014; 36(2):168-75. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24676047
205. Frishman WH, Mitta W, Kupersmith A, and Ky T. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev, 2006; 14(2):57-73. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16493243
206. Bagdas D, Muldoon PP, Zhu AZ, Tyndale RF, and Damaj MI. Effects of methoxsalen, a cyp2a5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology, 2014; 85:67-72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24859605
207. Alsharari SD, Siu EC, Tyndale RF, and Damaj MI. Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: Effects of methoxsalen, a cyp2a5/6 inhibitor. Nicotine & Tobacco Research, 2014; 16(1):18-25. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23884323
208. Sofuoglu M, Poling J, Mouratidis M, and Kosten T. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl), 2006; 184(3-4):645-51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16432681
209. Anthenelli RM, Blom TJ, McElroy SL, and Keck PE. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction, 2008; 103(4):687–94. Available from: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1360-0443.2008.02148.x
210. Arbaizar B, Gomez-Acebo I, and Llorca J. Decrease in tobacco consumption after treatment with topiramate and aripiprazole: A case report. J Med Case Rep, 2008; 2:198. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18547425
211. Khazaal Y and Zullino DF. Topiramate for smoking cessation and the importance to distinguish withdrawal-motivated consumption and cue-triggered automatisms. J Clin Psychopharmacol, 2009; 29(2):192-3; author reply 3-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19512990
212. Oncken C, Arias AJ, Feinn R, Litt M, Covault J, et al. Topiramate for smoking cessation: A randomized, placebo-controlled pilot study. Nicotine & Tobacco Research, 2014; 16(3):288-96. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24057996
213. Byars JA, Frost-Pineda K, Jacobs WS, and Gold MS. Naltrexone augments the effects of nicotine replacement therapy in female smokers. Journal of Addictive Diseases, 2005; 24(2):49-60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15784523
214. David S, Lancaster T, Stead LF, and Evins AE Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews, 2006 DOI: 10.1002/14651858.CD003086.pub2. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003086/frame.html
215. David SP, Chu IM, Lancaster T, Stead LF, Evins AE, et al. Systematic review and meta-analysis of opioid antagonists for smoking cessation. BMJ Open, 2014; 4(3):e004393. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24633528
216. David SP, Lancaster T, Stead LF, Evins AE, and Prochaska JJ. Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews, 2013; 6(6):CD003086. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23744347
217. Invion. Invion successfully completes phase 2 study of inv102 (nadolol) to aid smoking cessation. 2015. Available from: http://inviongroup.com/invion-successfully-completes-phase-2-study-of-inv102-nadolol-to-aid-smoking-cessation/
218. Drgon T, Johnson C, Walther D, Albino AP, Rose JE, et al. Genome-wide association for smoking cessation success: Participants in a trial with adjunctive denicotinized cigarettes. Mol Med, 2009; 15(7-8):268-74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19593411
219. David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, et al. Pharmacogenetics of smoking cessation in general practice: Results from the patch ii and patch in practice trials. Nicotine & Tobacco Research, 2011; 13(3):157-67. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21330274
220. Sturgess JE, George TP, Kennedy JL, Heinz A, and Muller DJ. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addict Biol, 2011; 16(3):357-76. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21362114
221. Saccone NL, Baurley JW, Bergen AW, David SP, Elliott HR, et al. The value of biosamples in smoking cessation trials: A review of genetic, metabolomic, and epigenetic findings. Nicotine & Tobacco Research, 2018; 20(4):403-13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28472521
222. Salloum NC, Buchalter ELF, Chanani S, Espejo G, Ismail MS, et al. From genes to treatments: A systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics, 2018; 19(10):861-71. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29914292
223. Nagelhout GE, Willemsen MC, van den Putte B, de Vries H, Willems RA, et al. Effectiveness of a national reimbursement policy and accompanying media attention on use of cessation treatment and on smoking cessation: A real-world study in the netherlands. Tobacco Control, 2015; 24(5):455-61. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24842854
224. Selby P, Brosky G, Oh P, Raymond V, Arteaga C, et al. A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (accessation). BMC Public Health, 2014; 14:433. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24885542
225. Reda AA, Kotz D, Evers SM, and van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database of Systematic Reviews, 2012; (6):CD004305. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22696341
226. Department of Health, The extension of the listing of nicotine patches on the pharmaceutical benefits scheme from 1 February 2011. Australian Government; 2013. Available from: http://www.pbs.gov.au/info/publication/factsheets/shared/Extension_of_the_listing_of_nicotine_patches.
227. Australian Institute of Health and Welfare. National Drug Strategy Household Survey, 2013 [computer file], 2015, Australian Data Archive, The Australian National University: Canberra.
228. Cooper J, Borland R, and Yong HH. Australian smokers increasingly use help to quit, but number of attempts remains stable: Findings from the international tobacco control study 2002-09. Australian and New Zealand Journal of Public Health, 2011; 35(4):368-76. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21806733
229. An LC, Schillo BA, Kavanaugh AM, Lachter RB, Luxenberg MG, et al. Increased reach and effectiveness of a statewide tobacco quitline after the addition of access to free nicotine replacement therapy. Tobacco Control, 2006; 15(4):286-93. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16885577
230. Grigg M and Glasgow H. Subsidised nicotine replacement therapy. Tobacco Control, 2003; 12(2):238-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12773740
231. Tinkelman D, Wilson SM, Willett J, and Sweeney CT. Offering free NRT through a tobacco quitline: Impact on utilisation and quit rates. Tobacco Control, 2007; 16 Suppl 1(suppl. 1):i42-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18048631
232. Maher JE, Rohde K, Pizacani B, Dent C, Stark MJ, et al. Does free nicotine replacement therapy for young adults prompt them to call a quitline? Tobacco Control, 2007; 16(5):357-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17897996
233. Hollis JF, McAfee TA, Fellows JL, Zbikowski SM, Stark M, et al. The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. Tobacco Control, 2007; 16 Suppl 1(suppl. 1):i53-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18048633
234. Cummings KM, Fix B, Celestino P, Carlin-Menter S, O'Connor R, et al. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. J Public Health Manag Pract, 2006; 12(1):37-43. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16340514
235. Cummings KM, Hyland A, Fix B, Bauer U, Celestino P, et al. Free nicotine patch giveaway program 12-month follow-up of participants. American Journal of Preventive Medicine, 2006; 31(2):181-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16829336
236. Bauer JE, Carlin-Menter SM, Celestino PB, Hyland A, and Cummings KM. Giving away free nicotine medications and a cigarette substitute (better quit) to promote calls to a quitline. J Public Health Manag Pract, 2006; 12(1):60-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16340517
237. Alberg AJ, Stashefsky Margalit R, Burke A, Rasch KA, Stewart N, et al. The influence of offering free transdermal nicotine patches on quit rates in a local health department's smoking cessation program. Addictive Behaviors, 2004; 29(9):1763-78. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15530720
238. O'Dea D. An economic evaluation of the quitline nicotine replacement therapy (NRT) service. June 28, 2004. Available from: http://www.ndp.govt.nz/moh.nsf/pagescm/1007/$File/economicevaluationquitline.pdf.
239. Bush TM, McAfee T, Deprey M, Mahoney L, Fellows JL, et al. The impact of a free nicotine patch starter kit on quit rates in a state quit line. Nicotine & Tobacco Research, 2008; 10(9):1511-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19023843
240. Walker N, Howe C, Bullen C, Grigg M, Glover M, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction, 2011; 106(6):1176-85. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21371155
241. Miller N, Frieden TR, Liu SY, Matte TD, Mostashari F, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: A prospective evaluation. Lancet, 2005; 365(9474):1849-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15924980
242. Watson D, Bullen C, Clover M, McRobbie H, Parag V, et al. Impact on quit attempts of mailed general practitioner 'brief advice' letters plus nicotine replacement therapy vouchers. J Prim Health Care, 2010; 2(1):4-10. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20690396
243. Jardin BF, Cropsey KL, Wahlquist AE, Gray KM, Silvestri GA, et al. Evaluating the effect of access to free medication to quit smoking: A clinical trial testing the role of motivation. Nicotine & Tobacco Research, 2014; 16(7):992-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24610399
244. Lundh A, Sismondo S, Lexchin J, Busuioc OA, and Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 2012; 12:MR000033. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23235689
245. Etter JF, Burri M, and Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: A meta-analysis. Addiction, 2007; 102(5):815-22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17493109
246. Greene NM, Taylor EM, Gage SH, and Munafo MR. Industry funding and placebo quit rate in clinical trials of nicotine replacement therapy: A commentary on etter et al. (2007). Addiction, 2010; 105(12):2217-8; author reply 9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21054610
247. Moberg CA and Humphreys K. Exclusion criteria in treatment research on alcohol, tobacco and illicit drug use disorders: A review and critical analysis. Drug Alcohol Rev, 2017; 36(3):378-88. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27324921
248. Motschman CA, Gass JC, Wray JM, Germeroth LJ, Schlienz NJ, et al. Selection criteria limit generalizability of smoking pharmacotherapy studies differentially across clinical trials and laboratory studies: A systematic review on varenicline. Drug and Alcohol Dependence, 2016; 169:180-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27863344
249. Kotz D, Brown J, and West R. Prospective cohort study of the effectiveness of smoking cessation treatments used in the "real world". Mayo Clinic Proceedings, 2014; 89(10):1360-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25282429
250. Piper ME, Bullen C, Krishnan-Sarin S, Rigotti NA, Steinberg ML, et al. Defining and measuring abstinence in clinical trials of smoking cessation interventions: An updated review. Nicotine & Tobacco Research, 2019. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31271211
251. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, et al. Biochemical verification of tobacco use and abstinence: 2019 update. Nicotine & Tobacco Research, 2019. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31570931
252. Catz SL, Jack LM, McClure JB, Javitz HS, Deprey M, et al. Adherence to varenicline in the compass smoking cessation intervention trial. Nicotine & Tobacco Research, 2011; 13(5):361-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21350041
253. Hollands GJ, McDermott MS, Lindson-Hawley N, Vogt F, Farley A, et al. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database of Systematic Reviews, 2015; 2(2):CD009164. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25914910
254. Hollands GJ, Naughton F, Farley A, Lindson N, and Aveyard P. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database of Systematic Reviews, 2019; 8:CD009164. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31425618
255. Schlagintweit HE, Perry RN, Darredeau C, and Barrett SP. Non-pharmacological considerations in human research of nicotine and tobacco effects: A review. Nicotine & Tobacco Research, 2019. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31058286
256. Pacek LR, McClernon FJ, and Bosworth HB. Adherence to pharmacological smoking cessation interventions: A literature review and synthesis of correlates and barriers. Nicotine & Tobacco Research, 2018; 20(10):1163-72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29059394
257. Fucito LM, Toll BA, Roos CR, and King AC. Smokers' treatment expectancies predict smoking cessation success. J Smok Cessat, 2016; 11(3):143-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27594921
258. Bailey SR, Fong DM, Bryson SW, Fortmann SP, and Killen JD. Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy. Journal of Substance Abuse Treatment, 2010; 39(2):150-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20598833
259. Hughes J. Ethical concerns about non-active conditions in smoking cessation trials and methods to decrease such concerns. Drug and Alcohol Dependence, 2009; 100(3):187–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19058924
260. Rosen L, Manor O, Engelhard D, and Zucker D. In defense of the randomized controlled trial for health promotion research. American Journal of Public Health, 2006; 96(7):1181-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16735622
261. Richter KP and Ellerbeck EF. It's time to change the default for tobacco treatment. Addiction, 2015; 110(3):381-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25323093
262. Ashcroft RE. The ethics of an opt-out default in tobacco treatment. Addiction, 2015; 110(3):389-90. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25678286